Stifel Nicolaus Begins Coverage on Lyell Immunopharma (NASDAQ:LYEL)

Equities research analysts at Stifel Nicolaus started coverage on shares of Lyell Immunopharma (NASDAQ:LYEL) in a report released on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $36.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 167.66% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. Citizens Jmp restated a “market outperform” rating and set a $34.00 price target on shares of Lyell Immunopharma in a research report on Monday, June 15th. Robert W. Baird set a $49.00 price objective on shares of Lyell Immunopharma and gave the company an “outperform” rating in a research note on Thursday, April 30th. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Finally, B. Riley Financial initiated coverage on shares of Lyell Immunopharma in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Lyell Immunopharma presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $13.45 on Thursday. Lyell Immunopharma has a 1 year low of $9.28 and a 1 year high of $45.00. The firm has a market capitalization of $329.52 million, a PE ratio of -0.97 and a beta of -0.04. The business’s 50 day moving average price is $13.55 and its 200-day moving average price is $19.10.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. As a group, analysts expect that Lyell Immunopharma will post -7.69 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GSK plc acquired a new position in Lyell Immunopharma during the fourth quarter worth $46,560,000. MWG Caph Ltd acquired a new position in Lyell Immunopharma during the 4th quarter worth about $31,030,000. ARCH Venture Management LLC boosted its holdings in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after acquiring an additional 938,438 shares during the period. Acadian Asset Management LLC grew its position in Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Lyell Immunopharma by 76.0% during the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock worth $12,651,000 after purchasing an additional 336,378 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.